Ovarian Cancer

Seiden, Michael V.

doi:10.1634/theoncologist.6-4-327

Cited by 18 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…infusion, which is a solution of paclitaxel in an adjuvant called Cremophor EL, which causes serious side effects such as hypersensitivity reactions, nephrotoxicity, neurotoxicity and cardiotoxicity (Kongshaug, Cheng, Moan, & Rimington, 1991;Mankad et al, 1992;Tatou et al, 1996;Webster et al, 1993). In recent years, various controlled delivery forms, such as polymeric micro/nanospheres, liposomes, micelles, parenteral emulsion, and prodrugs have been investigated to increase its solubility, to minimize the side effects as well as to avoid the use of toxic adjuvant (Denis et al, 1988;Gibbs, 2000;Holton, 1990;Jordan & Wilson, 2004;Markman, 2000;Perez, 1998;Seiden, 2001;Singla, Garg, & Aggarwal, 2002;Wani, Taylor, Wall, Coggon, & McPhail, 1971).…”

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel

Nanda¹,

Sasmal²,

Nayak³

2011

Carbohydrate Polymers

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel

Nanda¹,

Sasmal²,

Nayak³

2011

Carbohydrate Polymers

View full text Add to dashboard Cite

“…Additionally, paclitaxel itself is associated with peripheral neuropathy, which can add to the disease burden. 187 In a study of multimodal therapy, radiation therapy in combination with cisplatin alone, cisplatin plus fluorouracil and hydroxyurea, or hydroxyurea alone was assessed in women with locally advanced cervical cancer. 188 Both cisplatin groups achieved gains in overall survival and progression-free survival; however, patients who received radiation therapy plus the three-drug regimen experienced more leukopenia and other hematologic effects of grade 3 and grade 4 toxicity than did patients in the other two groups ( P <.001).…”

Section: Palliative Chemotherapy: Hrqol Implicationsmentioning

confidence: 99%

Contemporary Quality of Life Issues Affecting Gynecologic Cancer Survivors

Carter

Penson

Barakat

et al. 2012

Hematology/Oncology Clinics of North America

View full text Add to dashboard Cite

Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and 18% in the world.1 The most common gynecologic malignancies occur in the uterus and endometrium (53%), ovary (25%), and cervix (14%).2 Cervical cancer is most prevalent in premenopausal women, during their childbearing years, whereas uterine and ovarian cancers tend to present in the perimenopausal or menopausal period. Vaginal and vulvar cancers and malignancies arising from gestation, or gestational trophoblastic neoplasms, occur to a lesser extent. Regardless of cancer origin or age of onset, the disease and its treatment can produce short- and long-term sequelae (ie, sexual dysfunction, infertility, or lymphedema) that adversely affect quality of life (QOL). This article outlines the primary contemporary issues or concerns that may affect QOL and offers strategies to offset or mitigate QOL disruption. These contemporary issues are identified within the domains of sexual functioning, reproductive issues, lymphedema, and the contribution of health-related QOL (HRQOL) in influential gynecologic cancer clinical trials.

show abstract

“…Dexamethasone can have short-term adverse effects on salt and water retention, glucose tolerance, and susceptibility to some infections and can lead to cumulative effects such as myopathy (71). Peripheral neuropathy associated with paclitaxel therapy may be cumulative and may have a profound adverse effect on patient quality of life (72).…”

Section: Paclitaxelmentioning

confidence: 99%

Recurrent Ovarian Cancer

Herzog

2004

Clinical Cancer Research

137

View full text Add to dashboard Cite

Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response. Despite the large proportion of patients who relapse and undergo longer-term treatment, the question of optimal treatment duration has not been fully addressed to date. For patients who progress on therapy, the answer is straightforward: they are switched to another active agent, presumably having a different mechanism of action from previous therapies with, ideally, limited overlapping toxicities. However, for patients who remain in partial response or who have stable disease, the answer is less apparent and less clear. The majority of oncologists believe that treatment beyond 6 cycles of a given therapy does not provide any additional benefit to patients. There are some data to support that treatment strategy. However, with the advent of new, less toxic agents, treatment to progression should be further explored. Agents that are potentially well suited for extended treatment intervals may include such properties as absence of cumulative toxicity, non-cross-resistance, positive benefit on quality of life, and convenient schedule. A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment.

show abstract

Ovarian Cancer

Abstract: ABSTRACT

Cited by 18 publications

References 10 publications

Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel

Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel

Contemporary Quality of Life Issues Affecting Gynecologic Cancer Survivors

Recurrent Ovarian Cancer

Contact Info

Product

Resources

About